FDA-Inspected Site

Alexion Pharmaceuticals, Inc.

6 FDA inspections are on record for Alexion Pharmaceuticals, Inc. in Boston, United States.

Clean· No action indicated

Boston, United States · Last updated August 15, 2026

Overview

  • 6 FDA inspections are on record.
  • 2 inspections produced a Form 483.
  • The most recent recorded inspection date is 2026-07-01.

At a glance

Inspections

6

Form 483s

2

EIRs

0

Last outcome

Clean

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
15 Jun 2026 – 1 Jul 2026Human DrugsClean
3 Mar 2025 – 7 Mar 2025Human Drugs483View 483 →
30 Oct 2024 – 7 Nov 2024Human Drugs483View 483 →
31 Aug 2023 – 14 Sep 2023Human DrugsClean
21 Jun 2023 – 30 Jun 2023Human DrugsClean
16 Dec 2021 – 17 Dec 2021Human DrugsClean

Observations on record

Form 483 observations cited at this site, most recent first.

7 Mar 2025
FDCA 505-1(f)(4)

Failure to comply with REMS Implementation System

Cited by Meredith L Miller

7 Nov 2024
21 CFR 314.80(b)

Failure to develop written procedures

Cited by Kent A Conforti

7 Nov 2024
21 CFR 314.80(b)

Failure to review ADE information

Cited by Kent A Conforti

7 Nov 2024
21 CFR 314.80(c)(1)(i)

Late submission of 15-day report

Cited by Kent A Conforti

7 Nov 2024
21 CFR 314.80(c)(2)(ii)(B)

Late submission of an ICSR

Cited by Kent A Conforti

Investigators

FDA investigators tied to this site in the record.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 314.80(b)Cited across public-safe Form 483 observations2x
21 CFR 314.80(c)(1)(i)Cited across public-safe Form 483 observations1x
21 CFR 314.80(c)(2)(ii)(B)Cited across public-safe Form 483 observations1x
FDCA 505-1(f)(4)Cited across public-safe Form 483 observations1x

Full site report

Get the verbatim findings behind Alexion Pharmaceuticals, Inc.'s 2 Form 483s

Source PDFs and recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat